Gary Sirken, DO
Nephrology · Langhorne, PANPI 1164469334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,138 and has fallen 64.3% since, to $406 in 2025.
Across 206 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$673
- Amgen$300
- Bayer$273
- Fresenius USA Marketing, Inc.$265
- Vifor Pharma, Inc.$253
- plus $2K from 21 others
Across 12 payments — averaging $9613.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$94K
- Alnylam Pharmaceuticals Inc.$19K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Food & beverage$3,98091%
- Education$4029%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $1,034 |
| Otsuka America Pharmaceutical, Inc. | 26 | $673 |
| Amgen(2 entities) | 17 | $300 |
| Bayer | 16 | $273 |
| Fresenius USA Marketing, Inc. | 14 | $265 |
| Vifor Pharma, Inc. | 14 | $253 |
| OPKO Pharmaceuticals, LLC | 12 | $202 |
| Travere Therapeutics, Inc. | 6 | $167 |
| Novartis | 7 | $151 |
| Aurinia Pharma U.S., Inc. | 6 | $147 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $127 |
| Akebia Therapeutics Inc | 5 | $108 |
| Calliditas Therapeutics US Inc. | 4 | $105 |
| Lilly USA, LLC | 3 | $85 |
| Ardelyx, Inc. | 3 | $78 |
| Novo Nordisk | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Mallinckrodt Enterprises LLC | 2 | $47 |
| GSK | 3 | $42 |
| Boehringer Ingelheim | 2 | $41 |
| Shire North American Group Inc | 2 | $40 |
| Johnson & Johnson | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$191
How this compares
$4,382 in reported general payments places this provider in the 80th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 13 | $398,217 |
| JynarqueTolvaptan | 13 | $251,921 |
| FarxigaDapagliflozin Propanediol | 97 | $109,929 |
| RayaldeeCalcifediol | 32 | $43,309 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $27,216 |
| KerendiaFinerenone | 25 | $24,998 |
| EntrestoSacubitril/Valsartan | 15 | $16,759 |
| JardianceEmpagliflozin | 15 | $13,816 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $13,636 |
| Sevelamer Carbonate | 45 | $8,331 |
| Allopurinol | 255 | $2,427 |
| Calcitriol | 76 | $1,961 |
| Valsartan | 26 | $1,913 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,730 |
| Mycophenolate Mofetil | 17 | $1,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $300 | $398,21713 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $673 | $251,92113 claims |
| AstraZenecaFarxiga, Lokelma | $1,034 | $137,145132 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $202 | $43,30932 claims |
| BayerKerendia | $273 | $24,99825 claims |
| NovartisEntresto | $151 | $16,75915 claims |
| Boehringer IngelheimJardiance | $41 | $13,81615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Langhorne
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
- Katalin SusztakPhiladelphia$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.